Paes, Bosco http://orcid.org/0000-0002-3308-2706
,
Kim, Doyoung
Saleem, Mahwesh
Wong, Sophie
Mitchell, Ian
Lanctot, Krista L.
Funding for this research was provided by:
AbbVie (A05-130)
Article History
Received: 31 May 2018
Revised: 23 October 2018
Accepted: 14 December 2018
First Online: 4 January 2019
Compliance with ethical standards
:
: The Canadian RSV Evaluation Study of Palivizumab is funded by an investigator-initiated grant from AbbVie Canada. However, AbbVie had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Bosco Paes, Ian Mitchell, and Krista Lanctôt have received research funding from AbbVie Corporation and compensation as advisors or lecturers from AbbVie Corporation and MedImmune. Doyoung Kim, Mahwesh Saleem, and Sophie Wong declare they have no conflict of interest.
: Investigators in all 32 Canadian sites where the Canadian RSV Evaluation Study of Palivizumab study was conducted received ethical approval from their respective institutional research boards.
: All subjects were enrolled following full prior consent by parents or the legal guardian of the child.